Becker's Healthcare October 9, 2025
Ella Jeffries

The FDA has approved cemiplimab-rwlc, marketed as Libtayo, as the first immunotherapy for adjuvant treatment of cutaneous squamous cell carcinoma with a high risk of recurrence after surgery and radiation.

Tarrytown, N.Y.-based Regeneron Pharmaceuticals received approval Oct. 8 following a priority review. The decision...

Today's Sponsors

Venturous
ZeOmega

Today's Sponsor

Venturous

 
Topics: Biotechnology, FDA, Govt Agencies, Pharma, Pharma / Biotech
AI Model FDA-Cleared to Triage 14 Conditions
The Promise And Perils Of FDA’s New ‘Plausible Mechanism’ Pathway (Part 2)
FDA Updates Two Digital Health Final Guidance Documents
FDA in Flux — January 2026 Newsletter
The Promise And Perils Of FDA’s New ‘Plausible Mechanism’ Pathway (Part 1)

Share Article